Trial reportActa pharmacologica Sinica2009
N-acetylcysteine infusion reduces the resistance index of renal artery in the early stage of systemic sclerosis.
Trial report in Acta pharmacologica Sinica, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 24 citations in OpenAlex.
- The immunological benefit of higher dose N-acetyl cysteine following mechanical ventilation in critically ill patients.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2014Trial
- Iloprost infusion reduces serological cytokines and hormones of hypoxia and inflammation in systemic sclerosis patients.Clinical and experimental medicine · 2024Article
- Points to consider in renal involvement in systemic sclerosis.Rheumatology (Oxford, England) · 2017Review
- Left Ventricular Mass and Intrarenal Arterial Stiffness as Early Diagnostic Markers in Cardiorenal Syndrome Type 5 due to Systemic Sclerosis.Cardiorenal medicine · 2016Article
- Lipoic acid plays a role in scleroderma: insights obtained from scleroderma dermal fibroblasts.Arthritis research & therapy · 2014Article
- Evaluation of the renal resistive index and pulsatility index in patients with pleural effusion by duplex Doppler ultrasonography.Japanese journal of radiology · 2013Article
- Renal disease in scleroderma: an update on evaluation, risk stratification, pathogenesis and management.Current opinion in rheumatology · 2012Review
- Is spleen circulation impaired in systemic sclerosis and what is the role of liver fibrosis?World journal of gastroenterology · 2011Article
- Renal manifestations in scleroderma: evidence for subclinical renal disease as a marker of vasculopathy.International journal of rheumatology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate resistance index (RI) changes in renal artery after N-acetylcysteine infusion in patients with systemic sclerosis.
methodsIn an open-label study 40 patients with systemic sclerosis (SSc) were treated with N-acetylcysteine (NAC) iv infusion over 5 consecutive hours, at a dose of 0.015 g x kg(-1) x h(-1). Renal haemodynamic effects were evaluated by color Doppler examination before and after NAC infusion.
resultsNAC infusion significantly reduced RI in a group of sclerodermic patients with early/active capillaroscopic pattern, modified Rodnan Total Skin Score (mRTSS) <14 and mild-moderate score to the vascular domain of Medsger Scleroderma Disease Severity Scale (DSS). RI increased after NAC infusion in patients with late capillaroscopic pattern, mTRSS>14 and severe-end stage score to the vascular domain of DSS. In patients with reduction of RI after NAC infusion, diffusion capacity for carbon monoxide mean value was significantly higher than in those patients with an increase of RI. No significant differences in renal blood flow were found between patients with different subsets of SSc.
conclusionIn patients with low disease severity NAC ameliorates vascular renal function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.